BioInvent International (BINV.ST) Stock Analysis & AI Equity Report
BioInvent International (BINV.ST) overview
BioInvent International (BINV.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, BioInvent International reported revenue of SEK 44.7m and operating profit of SEK -471m; the year-end share price was 38.50 SEK and market capitalisation was SEK 2,533m. BioInvent International is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get BioInvent International's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About BioInvent International
BioInvent International AB is a clinical-stage biotechnology company focused on discovering and developing antibody-based therapies for cancer, with programs in hematological cancers and solid tumors. It uses its proprietary F.I.R.S.T. screening platform and n-CoDeR antibody library to generate candidates, and also earns revenue from research collaborations, licensing agreements, and contract manufacturing services.
Generate the BioInvent International report
BioInvent International is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for BioInvent International and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.